Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The PALM2 and AKAP2 fusion protein (PALM2AKAP2) results from a readthrough transcriptional fusion between the paralemmin 2 (PALM2) and A-kinase anchor protein 2 (AKAP2) genes, which are located adjacently on chromosome 9q31.3. It encodes a protein capable of binding the regulatory subunit (RII) of protein kinase A (PKA), likely acting as a scaffold to localize PKA activity to specific subcellular sites. This fusion is also called "paralemmin A kinase anchor protein". The fusion is protein-coding and exists as one of three protein isoforms derived from the locus: PALM2, AKAP2, and PALM2-AKAP2. The specific biological significance and functional impacts of the PALM2-AKAP2 fusion isoform are not well understood. However, the protein may integrate PKA signaling with downstream effectors and modulate the actin cytoskeleton. The gene/fusion has been identified in fusion events in several cancers, with reports of its involvement in prostate cancer and pan-cancer fusions, but there are no known drug interactions or established mechanisms of pharmacological action. It is not considered a therapeutic target or receptor, nor is it a characterized clinical biomarker. **Additional context and caveats:** - PALM2AKAP2 is a fusion gene/protein, not a typical therapeutic target such as a receptor, enzyme, transporter, or channel. - There is no evidence it functions as a classic drug target or that any approved drugs directly interact with it. - Most functional insights are extrapolated from domain knowledge regarding AKAP2 family scaffolds and general PKA signaling pathways, not from direct assay of the fusion protein itself. - Existence and function of the fusion isoform are more relevant to gene annotation, structural genomics, and cancer fusion databases than drug targeting or clinical biomarker utility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PALM2 and AKAP2 fusion protein (PALM2AKAP2).